CG Oncology to Present at Upcoming Investor Conferences in May
Rhea-AI Summary
CG Oncology (NASDAQ: CGON) will present at two investor conferences in May 2026. Arthur Kuan, CEO, and Ambaw Bellete, President & COO, will participate in fireside chats on May 12 at the Bank of America Health Care Conference (10:40–11:10 AM PT, Las Vegas) and May 20 at the RBC Global Healthcare Conference (2:35–3:00 PM ET, New York).
Live audio webcasts will be available via the company's Investor Relations website, with replays archived for approximately 90 days.
Positive
- None.
Negative
- None.
News Market Reaction – CGON
In the May 5 session, CGON declined 0.78%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
DALLAS, May 05, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced that Arthur Kuan, Chairman & Chief Executive Officer, and Ambaw Bellete, President & Chief Operating Officer, will participate in fireside chat presentations at the Bank of America Health Care Conference and the RBC Capital Markets Global Healthcare Conference this month. The details of the upcoming events are as follows:
Bank of America Health Care Conference 2026
Date: Tuesday, May 12, 2026
Presentation Time: 10:40 AM – 11:10 AM PT
Location: Las Vegas, NV
RBC Capital Markets Global Healthcare Conference
Date: Wednesday, May 20, 2026
Presentation Time: 2:35 PM – 3:00 PM ET
Location: New York, NY
Interested parties may access the live audio webcast for the conferences from the Investor Relations section of the company's website at www.cgoncology.com. The webcast replays will be available shortly after the conclusion of the live presentations and archived for approximately 90 days.
About CG Oncology
CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. CG Oncology sees a world where urologic cancer patients may benefit from our innovative immunotherapies to live with dignity and have an enhanced quality of life. To learn more, please visit: www.cgoncology.com.
Contacts
Media
Sarah Connors
Vice President, Communications and Patient Advocacy, CG Oncology
sarah.connors@cgoncology.com
Investor Relations
Megan Knight
Vice President, Investor Relations, CG Oncology
megan.knight@cgoncology.com